ANI Pharmaceuticals(US:ANIP)2026-02-27 14:00Financial Data and Key Metrics Changes - In Q4 2025, ANI Pharmaceuticals recorded revenues of $247.1 million, a 30% increase year-over-year, and full-year revenues reached $883.4 million, up 44% compared to 2024 [21][22] - Adjusted non-GAAP EBITDA for Q4 was $65.4 million, up 31% year-over-year, and for the full year, it was $229.8 million, reflecting a 47% increase [26] - Adjusted non-GAAP diluted earnings per share for Q4 was $2.33, compared to $1.63 in the prior year, and for the full year, it was $7.89, up from $5.20 [26] Business Line Data and Key Metrics Changes - Cortrophin Gel revenues in Q4 were $111.4 million, an 88% increase year-over-year, and full-year revenues were $347.8 million, up 76% [21][22] - The generics business generated $100.8 million in Q4, a 28% increase, and full-year revenues were $384.1 million, also up 28% [22] - ILUVIEN net revenues were $19.8 million in Q4 and $74.9 million for the full year [22] Market Data and Key Metrics Changes - The ACTH market approached $1 billion in sales in 2025 and is expected to grow significantly in 2026, with Cortrophin Gel projected to grow by 55%-65% [13] - The addressable patient population for gouty arthritis is approximately 10 million in the U.S., with only 36% receiving treatment annually [14] Company Strategy and Development Direction - ANI's strategic priorities for 2026 include transforming into a leading rare disease company, executing in the generics business, and maintaining disciplined capital allocation [10][11] - The company plans to maximize the growth opportunity for Cortrophin Gel by expanding its reach in nephrology, neurology, rheumatology, ophthalmology, and pulmonology [8][9] - A dedicated 90-person organization will focus on acute gouty arthritis flares to capture additional market opportunities [9][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the multi-year growth potential for Cortrophin, emphasizing the under-penetrated patient populations across various indications [38] - The company anticipates delivering over $1 billion in revenue for 2026, with rare disease expected to account for approximately 60% of total revenues [11][34] - Management noted that the first quarter of 2026 may see a sequential decline in Cortrophin revenues due to typical seasonality but expects significant growth in subsequent quarters [29][30] Other Important Information - ANI ended Q4 2025 with $285.6 million in unrestricted cash, up from $144.9 million at the end of the previous year [26] - The company has a gross leverage of 2.7 times and a net leverage of 1.5 times its full-year adjusted non-GAAP EBITDA [27] Q&A Session Summary Question: What is the multi-year opportunity for Cortrophin? - Management believes in significant multi-year growth opportunities for Cortrophin, highlighting under-penetrated patient populations and ongoing investments in commercial initiatives [38][39] Question: How will the royalty structure affect gross margins? - The blended royalty rate is expected to be in the high 20s for 2026, following the company surpassing the highest royalty tier in 2025 [39] Question: What is the expected operating leverage with the new sales force? - Management indicated that while they are investing in growth, they expect to maintain EBITDA margin percentages despite increased operating expenses [44][45] Question: What is the status of the phase 4 trial for Cortrophin? - The phase 4 trial is progressing, but results will not be available by the time the new sales force is fully deployed [68] Question: How is the company addressing patient access for ILUVIEN? - The company is navigating market access challenges through alternative access channels and is focused on growing awareness of ILUVIEN [70][71] Question: What is the product cadence for generics? - ANI plans to maintain a strong cadence of 10 to 15 product launches annually to support growth in the generics business [72]